Currently recommended prophylactic regimens for Plasmodium falciparum malaria are associated with a high incidence of adverse events and/or suboptimal efficacy. In a double-blind, placebocontrolled, randomized clinical trial in western Kenya, adult volunteers received a treatment course of atovaquone/proguanil hydrochloride (250 mg/100 mg per tablet) to eliminate preexisting infection. Immediately thereafter, subjects were randomized to one of the three prophylactic regimens to receive one atovaquone/proguanil tablet daily (n Å 68), two atovaquone/proguanil tablets daily (n Å 65), or placebo (n Å 65) for 10 weeks. The study endpoint for any subject was the development of parasitemia, evident on blood smear, during prophylaxis. Of the evaluable subjects, all in the low-dose (54 of 54) and high-dose (54 of 54) atovaquone/proguanil groups remained malaria-free during the 10-week prophylaxis period, in contrast to only 48% (26 of 54) in the placebo group (P õ .001). Both atovaquone/proguanil prophylactic regimens were as well tolerated as placebo. Thus, atovaquone/proguanil appears to be highly efficacious and safe as prophylaxis for P. falciparum malaria.
malarious area of western Kenya. All subjects were indigenous test for pregnancy. Thick blood films were stained with Giemsa stain, and malaria parasite counts were determined by the numKenyans. Subjects were excluded from the study if they were pregnant or unwilling to avoid pregnancy, were lactating, had ber of asexual parasites per 200 WBCs. A blood slide was not considered negative until an examination of 200 oil-immersion received drugs with antimalarial activity within the previous 2 weeks, had known hypersensitivity to atovaquone or proguanil, fields showed no parasites. Hematology values monitored included hemoglobin, hemahad abnormal baseline hematologic or clinical chemistry laboratory values, had significant renal impairment (defined as a tocrit, platelets, total WBC count, and lymphocyte count. Biochemistry values monitored included sodium, potassium, albucreatinine clearance of õ30 mL/min), had undergone a splenectomy, had laboratory values suggestive of hepatitis (i.e., a min, creatinine, urea, total bilirubin, alkaline phosphatase, and alanine transaminase. Following their screening visit, eligible threefold increase above the normal upper limit of alanine transaminase), or had clinically significant concomitant medivolunteers began the 3-day atovaquone/proguanil curative treatment regimen, followed immediately by chemosuppression cal problems, as determined by the investigators. All subjects gave informed consent.
for at least 10 weeks. On a weekly basis, volunteers were questioned regarding adverse events, and their vital signs were assessed, a malarial Study Design blood smear was obtained, and concomitant medication was reviewed. Physical examination, hematology/biochemistry This comparative clinical trial was double-blind, placebocontrolled, randomized, three-armed, and parallel-grouped in measurements, and a blood pregnancy test were done after 5 and 10 weeks of prophylaxis. Those whose chemoprophylaxis design. The study was conducted in Lwak village in western Kenya during the main malaria-transmission season, between failed were treated with pyrimethamine/sulfadoxine and appropriate supportive care. During the 4-week follow-up period, April and August 1996. This site was chosen because ú95% of malaria cases are due to P. falciparum, there is intense thick blood films and adverse events were assessed weekly. perennial transmission of falciparum malaria, and chloroquine resistance is widespread. The protocol for this study was re-
In Vitro Susceptibility Studies
viewed and approved by the institutional review board of Kenya and by the U.S. Army Surgeon General.
The IC 50 value (concentration of drug that inhibits parasite growth by 50% in vitro) of atovaquone, proguanil, and cycloguanil for falciparum isolates was measured after atovaquone/ Treatment Assignment proguanil chemoprophylaxis in all subjects who developed parAll subjects initially received a curative treatment regimen asitemia and from whom viable parasites could be obtained. of four tablets, each containing 250 mg of atovaquone and 100
Post-chemoprophylaxis IC 50 values were compared with histormg of proguanil hydrochloride (Malarone; Glaxo Wellcome, ical IC 50 values reported in Kenya (prior to 1996) to investigate Research Triangle Park, NC), administered once daily for 3 the possible development of drug resistance. days. Subjects were then randomized to 1 of 3 suppressive prophylactic regimens for 10 weeks (70 days), to receive 1 atovaquone/proguanil tablet plus 1 placebo tablet, 2 atovaSafety Analysis quone/proguanil tablets, or 2 placebo tablets daily. Because Adverse events were listed together with each event's intenpharmacokinetic studies have shown that ingestion of food sity, investigator-attributed causality, onset, and cessation. All increases the bioavailability of atovaquone [21] , all treatment safety data were listed and clinical laboratory values outside regimens were administered with a small meal. Dosing was the normal range were highlighted. done under the supervision of trained field workers, and compliance was confirmed by tablet count.
Statistical Analysis

Clinical Assessment and Efficacy Endpoints
It was estimated that 70 subjects in each of the two active treatment groups would provide a power of 80% to detect an The efficacy endpoint was the proportion of subjects developing patent parasitemia during atovaquone/proguanil chemo-85% protective efficacy compared to placebo, with a lower limit of confidence of Ç70%, if the placebo infection rate was prophylaxis, compared to its incidence in the placebo control group. The first confirmed instance of malaria parasitemia ocassumed to be 85%. A per-protocol analysis of the study results was performed, as this is more clinically relevant. The prophycurring after curative treatment and during the daily administration of study drug was considered a failure of prophylaxis.
lactic success proportions were compared by considering the 2 1 2 frequency table and performing a Fisher's exact test At the screening visit subjects reported their medical history and underwent a physical examination, vital signs and hematolseparately for the two comparisons: low-dose atovaquone/proguanil vs. placebo and high-dose atovaquone/proguanil vs. plaogy/biochemistry values were evaluated, a malaria blood smear (on a thick blood film) was obtained, and females had a blood cebo.
A Bonferroni adjustment was applied when interpreting The three chemoprophylaxis groups at screening were similar with respect to demographic characteristics (table 1) . Thirtythe P values. A point estimate and exact 95% confidence interval were also calculated for the percent efficacy, for four percent of the subjects had positive malaria smears at screening, all of whom had negative smears at the first visit which this equation was used: percent efficacy Å 100 1 (1 0 [failure rate in atovaquone/proguanil hydrochloride following the 3-day curative treatment course of atovaquone/ proguanil. The majority of subjects with parasitemia at screengroup/failure rate in placebo group]). A failure of chemoprophylaxis was defined by either a positive blood smear (for ing were symptomatic. The types of medications taken concomitantly by the subjects during the study (not shown) did not any Plasmodium species) or withdrawal due to a treatmentrelated adverse event.
differ among the treatment groups. Eighty-three percent of the randomized subjects took other medications, usually analgesics The per-protocol population was defined as those subjects who were randomized to receive either placebo or atovaquone/ and antipyretics (75%), antihistamines (54%), beta-lactam antibiotics (53%), ophthalmologicals (51%), nonsteroidal antiinproguanil during chemosuppression, who received at least one dose of treatment during chemosuppression, who were protoflammatory agents (44%), topical products for joint or muscular pain (44%), or hypnotics and sedatives (37%). col-compliant with regard to receiving medication, who did not receive concomitant medication that could influence the evaluation of efficacy, and who had a negative baseline smear
Prophylactic Efficacy
following the 3-day curative treatment regimen and were present at week 10 (or had treatment failure before then). Subjects Parasitemia developed in 28 (52%) of the subjects treated with placebo and none of the subjects treated with either lowwho withdrew for any reason other than parasitemia or a treatment-related adverse event were excluded from the per-protodose or high-dose atovaquone/proguanil. Thus, prophylactic efficacy and success rates in both the low-dose and high-dose col population. No hypothesis-testing was carried out on safety or demographic variables. A difference was considered statistiatovaquone/proguanil treatment groups were 100% (table 2) . The difference in success rates between placebo and the cally significant if the P value was õ.05.
atovaquone/proguanil treatment groups was highly significant (P õ .001).
Results
In Vitro Susceptibility Demographic and Baseline Characteristics
No indication of resistance to the atovaquone/proguanil combination was observed. The mean in vitro IC 50 values of atova-A total of 216 volunteers were screened and enrolled in the 3-day curative treatment phase of the trial. Two-hundred and quone for falciparum isolates obtained post-chemoprophylaxis (1.22 nM [range, 0.27 -2.5 nM; n Å 17]) remained within the five volunteers completed the curative phase and were randomized to receive treatment with 1 atovaquone/proguanil tablet range observed prior to 1996 (1.73 nM [range, 0.6 -5.0 nM; n Å 22]). Similarly, the mean in vitro IC 50 values of proguanil daily (n Å 68), 2 atovaquone/proguanil tablets daily (n Å 70), or placebo (n Å 67). Seven of these subjects (3 in the placebo (10,400 nM [range, 3,510 -17,300; n Å 10]) and cycloguanil (16.5 nM [range, 3.5 -44.1 nM; n Å 12]) for falciparum isolates group, 2 in the low-dose group, and 2 in the high-dose group) were lost to follow-up before they had a baseline smear obwere unchanged after atovaquone/proguanil chemoprophylaxis, in comparison with the range for historical data. tained and thus were included in the safety population but excluded from the efficacy population.
A total of 162 subjects (82%; 54 in each treatment group) Safety completed the study and were evaluable for the efficacy analysis. Of the 36 unevaluable subjects, 12 (4 receiving lowBoth regimens of atovaquone/proguanil were well tolerated. The type and frequency of drug-related adverse events with dose atovaquone/proguanil, 2 receiving high-dose atovaquone/proguanil, and 6 receiving placebo) failed to return to each regimen were no different from those observed with placebo (table 3) . The two atovaquone/proguanil regimens did not the clinic and 15 (6, 7, and 2, respectively) did not have a blood smear result for week 10. Of the other unevaluable differ in any way with regard to adverse events. The most commonly reported adverse events were dyspepsia and gastrisubjects, three receiving low-dose atovaquone/proguanil and two receiving placebo were withdrawn because of noncomtis, which occurred with a frequency of 6% -12% and 7% -9%, respectively, in the atovaquone/proguanil treatment groups pliance. Other withdrawals were due to the use of a disallowed concomitant medication (1 subject receiving placebo and 13% and 7%, respectively, in the placebo group. Five subjects experienced serious adverse events (necessitatand 1 subject receiving high-dose atovaquone/proguanil), refusal to allow drawing of blood (1 subject in the low-dose ing hospitalization) during the study. One subject experienced repeated vomiting during the initial 3-day clearance phase of atovaquone/proguanil group), and mistaken enrollment (violation of inclusion/exclusion criteria; 1 subject receiving the trial, and this event was considered probably drug-related. Two subjects in the placebo group had adverse events that were high-dose atovaquone/proguanil). NOTE. Seven subjects, 3 in the placebo group, 2 in the low-dose group, and 2 in the high-dose group, were randomized to treatment but were lost to follow-up before they had a baseline smear performed and thus are included in the safety population but excluded from the efficacy population.
* Patients who did not complete the 10-week prophylaxis treatment period for reasons other than the development of parasitemia.
not considered drug-related (an infected skin ulcer and shigella nil treatment group was hospitalized for complicated cellulitis, which was considered unrelated to medication. There were no dysentery), while a third subject in the placebo group had an adverse event that was considered possibly related (head, chest, clinically important differences in abnormal laboratory values among the three chemoprophylaxis groups (data not shown). and back pains). One subject in the low-dose atovaquone/progua- exoerythrocytic forms in the liver as well as inhibiting schizog-
ony of the erythrocytic forms [15] . Proguanil can also inhibit development in the mosquito stage of malaria and thus prevent Dyspepsia 9 (13) 4 (6) 8 (12) transmission. The active metabolite of proguanil, cycloguanil, Gastritis 5 (7) 6 (9) 5 (7) has an IC 50 against various sensitive strains of P. falciparum
Abdominal pain 4 (6) 5 (7) 3 ( (1) 3 (4) ing ú500 patients in Thailand, the Philippines, Gabon, Kenya, Diarrhea 3 (4) 2 (3) 3 (4) Peru, and Brazil have shown an overall cure rate of ú98% multidrug-resistant malaria in Southeast Asia and Latin America suggests that the efficacy shown in the present study may be applicable to malaria prevention outside of Africa. The use of the 2.5:1 mg/mg ratio in the atovaquone/proguanil Discussion fixed-dose combination has been previously shown to provide optimal synergy against P. falciparum isolates [17, 20] . Earlier The results of this study indicate that prophylaxis with either one or two tablets containing 250 mg of atovaquone and 100 studies showed that use of atovaquone and proguanil as single entities led to unacceptably high rates of recrudescence because mg of proguanil hydrochloride, taken once daily for 10 weeks, prevents falciparum malaria in 100% of subjects in an area of of the development of resistance, but resistant parasites rarely developed after treatment with these two drugs in combination the world where this type of malaria is highly endemic. The participants in this trial are assumed to have substantial immu- [17] . It is theorized that because antimalarial drug combinations expose malarial parasites to drugs with diverse modes of action, nity to symptoms due to malaria, as seen in adults in areas of endemicity, but this does not protect them from patent infection they reduce the probability that the parasites will develop resistance to both constituent drugs [32] . [22] . This is the first study to evaluate the efficacy of the atovaThus, combinations like atovaquone/proguanil may lower the probability of multiple mutations at independent loci, makquone/proguanil combination as prophylaxis for malaria in adults, and it confirms the results of a recent study in children in ing resistance less likely. The evolution of drug-resistant strains of P. falciparum to the combination of atovaquone and proguaGabon [23] . The findings of this study are noteworthy because currently recommended prophylactic regimens are no longer nil hydrochloride cannot be ignored because of the rapidity with which resistance develops to either of the single agents achieving total prevention in geographic areas where intense malarial transmission is prevalent. A trial conducted in the alone. The absence of any such resistance appearing during this initial field trial is reassuring but inconclusive. The develsame geographic area in Kenya in 1993 produced efficacy rates of 54% for chloroquine plus proguanil, 77% for mefloquine, opment of drug resistance is always a factor for any new antimicrobial drug, but it is minimized by the use of the two syner-84% for doxycycline, and 85% for primaquine [24] . Furthermore, concern about adverse events reported by travelers taking gistic drugs in a relatively short-acting combination. The safety data from this study confirm that atovaquone/ current prophylactic regimens has increased the need for welltolerated medications with proven safety records.
proguanil is well tolerated and, at prophylactic doses, the frequency of adverse events is no higher than in placebo recipiThe effectiveness of the atovaquone/proguanil combination as prophylaxis for falciparum malaria was not unexpected. In ents. A low incidence of drug-related adverse events with atovaquone alone previously has been shown in clinical trials vitro, atovaquone has an IC 50 value against various P. falciparum strains of 0.7 -4.3 nM, and it is consistently more potent evaluating its efficacy in the prophylaxis and treatment of Pneumocystis carinii pneumonia and toxoplasmic encephalitis at than chloroquine, which has an IC 50 value for the same strains of 74 -633 nM [25, 26] . In addition to blood schizonticidal doses of up to 3,000 mg daily for 18 weeks [33, 34] . Similarly, a postmarketing surveillance study has shown that proguanil, activity, atovaquone has potent activity against the liver stages of rodent malaria [27, 28] and has recently been shown to administered at doses of 100 -200 mg daily for an average of 7 weeks, was well tolerated by an estimated 60,000 subjects have causal prophylactic activity in humans challenged with P. falciparum infection [29] . Activity is also seen against the receiving the drug for malaria prophylaxis [35] . Although gastrointestinal adverse events and headache have early gametocyte stage and against mosquito stages, which might have important consequences for preventing transmisbeen reported in clinical trials evaluating the atovaquone/proguanil combination for treatment of falciparum malaria [30], sion of resistant parasites [10] .
